Nectin Therapeutics Enters Global, Exclusive License Agreement With Immunome; Immunome Receives Exclusive Rights To Panel Of Antibodies Targeting An Undisclosed Target
Author: Benzinga Newsdesk | July 25, 2024 07:41am
Under the terms of the agreement, Nectin granted Immunome an exclusive, worldwide, all-fields license to monoclonal antibodies that are directed to a single undisclosed target. Immunome will be responsible for the research, development, manufacturing and commercialization of products incorporating these antibodies. Nectin will receive an upfront payment and will be eligible for milestones and royalties.
Posted In: IMNM